MMP7 Drives EMT and Fibrosis via E-cadherin/β-Catenin in Biliary Atresia

Study Background and Research Question

Biliary atresia (BA) is a rare but rapidly progressive pediatric liver disease marked by fibro-inflammatory destruction of the biliary system. The primary clinical challenge in BA is relentless liver fibrosis, which often leads to cirrhosis and necessitates early transplantation. While the Kasai portoenterostomy (KPE) can restore bile flow in some patients, many continue to develop intrahepatic fibrosis even after surgery, underlining the need for a deeper mechanistic understanding and more effective therapeutics. Although matrix metalloproteinase 7 (MMP7) has emerged as a specific biomarker for BA and is implicated in tissue remodeling, its direct role in fibrosis progression and the underlying molecular pathways remained insufficiently defined (internal review).

Key Innovation from the Reference Study

The reference study by Rong et al. provides a significant advance by elucidating how MMP7 mediates liver fibrosis in BA through the induction of epithelial–mesenchymal transition (EMT) in biliary epithelial cells (BECs). Specifically, the research demonstrates that MMP7 cleaves E-cadherin, disrupting cellular adhesion and triggering β-catenin nuclear translocation—a key event in the Wnt signaling pathway. By establishing a mechanistic link between MMP7 elevation, E-cadherin/β-catenin pathway activation, and EMT-driven fibrogenesis, the study identifies MMP7 not only as a marker but also as a driver and therapeutic target in BA-associated fibrosis (reference).

Methods and Experimental Design Insights

The research integrated patient-derived clinical data, transcriptomic analysis, in vitro cell models, and in vivo mouse studies:

• Clinical correlation: Serum and liver tissue samples from BA patients were analyzed for MMP7 expression and correlated with fibrosis severity.
• Gene set enrichment analysis (GSEA): Public GEO datasets were mined to explore biological processes associated with MMP7, leading to the identification of EMT as a major downstream process.
• In vitro functional studies: Human intrahepatic biliary epithelial cells (HIBEpiCs) were treated with recombinant MMP7 to assess EMT induction and E-cadherin cleavage.
• In vivo mouse model: Chronic BA was modeled in mice to examine the profibrotic effects of MMP7 and the impact of its inhibition using antibody-based blockade.

This multi-layered approach allowed the authors to validate clinical associations, dissect mechanistic pathways, and evaluate therapeutic potential in a translational context.

Core Findings and Why They Matter

The study reports several interlocking discoveries:

• MMP7 upregulation correlates with fibrosis: Both liver tissue and serum levels of MMP7 were strongly associated with histological fibrosis in BA patients.
• EMT as a central pathway: GSEA and EMT scoring in patient samples linked high MMP7 expression with a pronounced EMT signature in BECs.
• Mechanism: E-cadherin/β-catenin axis: In vitro, MMP7 treatment resulted in E-cadherin cleavage, loss of cell–cell adhesion, and increased nuclear β-catenin, all hallmarks of EMT and Wnt pathway activation.
• Therapeutic inhibition: Blocking MMP7 in the BA mouse model reduced EMT markers and alleviated liver fibrosis, supporting the concept of MMP7 as a tractable anti-fibrotic target.

These findings clarify the molecular progression from MMP7 elevation to EMT and fibrosis, emphasizing that targeting the E-cadherin/β-catenin/Wnt signaling axis may disrupt this pathogenic cascade. Given the limited efficacy of current adjunctive therapies in BA, these mechanistic insights provide a foundation for rational therapeutic development.

Comparison with Existing Internal Articles

Several internal reviews have explored the role of Wnt/β-catenin pathway inhibition in EMT and fibrosis models. Notably, the article "ICG001: Wnt/β-Catenin Pathway Inhibitor in EMT and Fibrosis Models" highlights the utility of selective Wnt/β-catenin antagonists for dissecting EMT-driven fibrogenesis. These reviews elaborate on the practical use of pathway inhibitors, such as ICG001, in both in vitro and in vivo studies targeting CBP/β-catenin interactions. The new evidence from Rong et al. provides a direct mechanistic rationale for deploying such inhibitors in BA and similar fibrotic contexts, as MMP7-driven EMT operates through the very pathway that these agents modulate.

Another relevant internal resource, "ICG001: Advancing Wnt/β-Catenin Targeting in Translational Fibrosis Research", reviews translational workflows and emphasizes the importance of pathway-selective inhibition for high-fidelity EMT studies. The present reference study substantiates these workflows by demonstrating the centrality of β-catenin in BA fibrosis progression.

Limitations and Transferability

While the study presents compelling evidence for the MMP7–E-cadherin/β-catenin–EMT axis in BA, several considerations temper the immediate clinical translation:

• Model system scope: The in vitro findings are based on primary human BECs, and in vivo efficacy is demonstrated in a chronic BA mouse model. While both are robust, species differences and the complexity of human BA progression warrant further validation.
• Therapeutic specificity: The blockade of MMP7, though effective in reducing fibrosis, may have off-target effects and requires careful dosing and safety evaluation in pediatric contexts.
• Pathway crosstalk: The Wnt/β-catenin pathway is involved in multiple regenerative and developmental processes, raising concerns about side effects in systemic inhibition.
• Long-term outcomes: The study focuses on histological and molecular markers; impacts on long-term liver function and survival remain to be determined.

Nevertheless, the mechanistic clarity achieved by linking MMP7 activity to EMT via the E-cadherin/β-catenin axis provides a strong platform for subsequent translational research.

Protocol Parameters

• MMP7 stimulation in vitro: Treat human intrahepatic biliary epithelial cells with recombinant MMP7 at concentrations and durations optimized for EMT induction, as validated in the reference study.
• EMT marker assessment: Measure E-cadherin cleavage and β-catenin nuclear localization via immunofluorescence and Western blot analysis 24–48 hours post-treatment.
• In vivo MMP7 inhibition: Administer anti-MMP7 antibody or small molecule inhibitor to BA mouse models at doses titrated to reduce serum and hepatic MMP7, monitoring liver fibrosis by histology and molecular markers after 2–4 weeks.
• Wnt/β-catenin pathway inhibition: For studies extending these findings, consider using selective inhibitors such as ICG001 at 10 µM for 24 hours in vitro, as supported by product information and internal workflow articles.

Research Support Resources

For researchers aiming to dissect the role of the Wnt/β-catenin pathway in EMT-driven fibrosis, especially in models where MMP7 or E-cadherin/β-catenin interactions are central, selective inhibitors represent valuable tools. ICG001 (SKU A8217) from APExBIO is a potent, pathway-selective Wnt/β-catenin inhibitor that antagonizes the CBP/β-catenin interaction without affecting p300. It is frequently used at 10 µM for 24-hour in vitro protocols and has demonstrated efficacy in various fibrosis and cancer models, including those involving EMT. Details on solubility, storage, and recommended workflows are available on the product page. Incorporating such pathway-selective tools can facilitate the mechanistic and therapeutic studies inspired by the findings of Rong et al.